In a sudden decision, AstraZeneca's chair Shaun Grady announced the cancellation of a planned 450m expansion of its childhood flu vaccine factory in Merseyside after a lengthy negotiation process. The announcement followed the Chancellor's speech praising AstraZeneca for its role in UK growth. This expansion, aimed at enhancing the UK's pandemic readiness, faced delays attributed to bureaucratic hurdles and inefficiencies in government support mechanisms. Previous investment losses in the sector, like GSK's withdrawal, highlight ongoing challenges in fostering a conducive environment for pharmaceutical development in the UK.
AstraZeneca’s planned 450m expansion in Merseyside has been abruptly halted, just hours after government praise for their contributions to the UK economy.
Months of negotiations over state support for AstraZeneca’s vaccine project collapsed, signaling an urgent need for improved cooperation between government and pharmaceutical companies.
Collection
[
|
...
]